Soligenix, Inc. (SNGX) stock
SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.28−0.01 (-2.67%)
Close on Nov 17, 2026Market cap $6.11MP/E –Yield –
Soligenix ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Soligenix's ebitda for the twelve months ending Mar 31, 2022 was -$15.02M. For fiscal 2021 it was -$13.06M. The highest annual figure on record is -$2.73M in fiscal 2011.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | -$13.06M | – |
| FY2020 | Dec 31, 2020 | -$18.52M | – |
| FY2019 | Dec 31, 2019 | -$10.49M | – |
| FY2018 | Dec 31, 2018 | -$9.01M | – |
| FY2017 | Dec 31, 2017 | -$7.53M | – |
| FY2016 | Dec 31, 2016 | -$5.62M | – |
| FY2015 | Dec 31, 2015 | -$6.86M | – |
| FY2014 | Dec 31, 2014 | -$10.52M | – |
| FY2013 | Dec 31, 2013 | -$6.93M | – |
| FY2012 | Dec 31, 2012 | -$4.46M | – |
| FY2011 | Dec 31, 2011 | -$2.73M | – |
| FY2010 | Dec 31, 2010 | -$7.69M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2022 | Mar 31, 2022 | -$4.18M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.50M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.36M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.98M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.22M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.48M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.80M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.80M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.46M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.29M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.15M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.91M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.58M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.38M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.56M | – |
| Q3 FY2017 | Sep 30, 2017 | -$951.65K | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.30M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.72M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.27M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.48M | – |
| Q2 FY2016 | Jun 30, 2016 | -$987.13K | – |
| Q1 FY2016 | Mar 31, 2016 | -$1.88M | – |
See a number that looks wrong?